Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.
Vortex Energy Corp. Announces Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 13, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OT...
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Is Writing A New Playbook For Pharma R&D. And It's Working.
Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the ...
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
Vertex Pharmaceuticals is inching closer to a new approval in its central therapeutic area. The company's lineup is getting stronger, and its pipeline is progressing smoothly.
Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Stree...
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.
Vertex Pharmaceuticals, Inc. (VRTX) Q1 2024 Earnings Call Transcript
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart A...
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.05 per share a year ago.
Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
Vertex is a leader in cystic fibrosis treatment but also is showing it can succeed in other disease areas. The company recently won approval for a gene-editing treatment for blood disorders.
Related Companies